TCW Group
REGN icon

TCW Group’s Regeneron Pharmaceuticals REGN Stock Holding History

TCW Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.26M Sell
1,667
-28
-2% -$21.2K 0.01% 301
2026
Q2 		$1.06M Buy
1,695
+30
+2% +$20.4K 0.01% 378
2026
Q1 		$1.29M Sell
1,665
-374
-18% -$286K 0.01% 327
2025
Q4 		$1.57M Buy
+2,039
New +$1.38M 0.01% 304
2015
Q2 		– Sell
-21,450
Closed -$9.7M – 708
2015
Q1 		$9.7M Buy
21,450
+650
+3% +$275K 0.05% 255
2014
Q4 		$8.53M Sell
20,800
-15,350
-42% -$6.04M 0.04% 296
2014
Q3 		$13M Sell
36,150
-3,850
-10% -$1.29M 0.05% 275
2014
Q2 		$11.3M Buy
40,000
+850
+2% +$252K 0.05% 313
2014
Q1 		$11.8M Buy
39,150
+300
+0.8% +$92.4K 0.05% 299
2013
Q4 		$10.7M Buy
38,850
+350
+0.9% +$101K 0.05% 319
2013
Q3 		$12M Buy
38,500
+1,050
+3% +$276K 0.06% 274
2013
Q2 		$8.42M Buy
+37,450
New +$8.72M 0.04% 339

Other funds holding REGN

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

TCW Group's REGN Position: Q3 2026 in Review

TCW Group reduced its Regeneron Pharmaceuticals (REGN) stake by 1.7% in Q3 2026, selling an estimated $21.2K and leaving 1,667 shares worth $1.26M. The position accounts for 0.01% of the portfolio, ranked #301.

TCW Group first reported a position in REGN in Q2 2013 and has held it in 12 quarters since. The position peaked at $13M in Q3 2014. 1,212 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • TCW Group held 1,667 shares of Regeneron Pharmaceuticals worth $1.26M as of Q3 2026.
  • TCW Group sold 28 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $21.2K.
  • Regeneron Pharmaceuticals made up 0.01% of TCW Group's portfolio in Q3 2026, its #301 holding.
  • TCW Group first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 12 quarters since.
  • TCW Group's Regeneron Pharmaceuticals position peaked at $13M in Q3 2014.
  • 1,212 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on TCW Group's 13F filing for Q3 2026, filed 10 Nov 2026.